naltrexone has been researched along with HIV in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Brown, ST; Bryant, KJ; Edelman, EJ; Fiellin, DA; Fiellin, LE; Hansen, N; Holt, SR; Justice, AC; Kyriakides, TC; Moore, BA; Virata, M | 1 |
Douglas, SD; Guo, CJ; Ho, WZ; Li, Y; Tian, S; Wang, X | 1 |
1 trial(s) available for naltrexone and HIV
Article | Year |
---|---|
Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Anti-Retroviral Agents; CD4 Lymphocyte Count; Counseling; Delayed-Action Preparations; Double-Blind Method; Female; HIV; HIV Infections; Humans; Injections, Intramuscular; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2019 |
1 other study(ies) available for naltrexone and HIV
Article | Year |
---|---|
Morphine enhances HIV infection of human blood mononuclear phagocytes through modulation of beta-chemokines and CCR5 receptor.
Topics: Chemokines, CC; DNA Replication; DNA, Viral; Dose-Response Relationship, Drug; HIV; Humans; Macrophages; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Phagocytosis; Receptors, CCR5; Species Specificity; Up-Regulation; Virus Replication | 2002 |